Economic evaluation of vaccination programme of 7-valent pneumococcal conjugate vaccine to the birth cohort in Japan

Vaccine

Volumn 30, Issue 22, 2012, Pages 3320-3328

  Hoshi, Shu ling ^a   Kondo, Masahide ^a   Okubo, Ichiro ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Budget impact analysis; Cost effectiveness analysis; Pneumococcal conjugate vaccine; Vaccination programme

Indexed keywords

PNEUMOCOCCUS VACCINE;

ARTICLE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; FUNDING; HEALTH PROGRAM; HIDDEN MARKOV MODEL; HUMAN; JAPAN; PRIORITY JOURNAL; PRODUCTIVITY; VACCINATION;

CHILD, PRESCHOOL; COSTS AND COST ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; JAPAN; MODELS, STATISTICAL; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84859860554     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.02.033     Document Type: Article

References (43)

1. Advisory Committee on Immunization Practices Progress in introduction of pneumococcal conjugate vaccine-worldwide, 2000-2008. MMWR Recomm Rep 2008, 57(42):1148-1151.
2. Claes C., Reinert R.R., von der Schulenburg J.M. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. Eur J Health Econ 2009, 10(1):25-38.
3. Hubben G.A., Bos J.M., Glynn D.M., van der Ende A., van Alphen L., Postma M.J. Enhanced decision support for policy makers using a web interface to health-economic models-illustrated with a cost-effectiveness analysis of nation-wide infant vaccination with the 7-valent pneumococcal conjugate vaccine in the Netherlands. Vaccine 2007, 25(18):3669-3678.
4. McIntosh E.D., Conway P., Willingham J., Hollingsworth R., Lloyd A. Pneumococcal pneumonia in the UK-how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine 2005, 23(14):1739-1745.
5. Melegaro A., Edmunds W.J. Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales. Vaccine 2004, 22(31-32):4203-4214.
6. Silfverdal S.A., Berg S., Hemlin C., Jokinen I. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine. Vaccine 2009, 27(10):1601-1608.
7. Tilson L., Usher C., Butler K., Fitzsimons J., O'Hare F., Cotter S., et al. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland. Value Health 2008, 11(5):898-903.
8. Preventive Vaccination Law, Supplementary Provisions, Extract, Pub. L. No. 116, Article 2; November 7, 2001.
9. Trueman P., Drummond M., Hutton J. Developing guidance for budget impact analysis. Pharmacoeconomics 2001, 19:609-621.
10. Health Service Burea Yobou sessyu ni kakawaru hiyou hutan genjyo ni tuite 2010, Ministry of Health, Labour and Welfare, Tokyo, [in Japanese].
11. Ministry of Health, Labour and Welfare Shikyukeigan nado wakutin sessyukinkyu sokusin jigyou no jissi ni tsuite. Kenhatsu 1126 no. 10 2010, Ministry of Health, Labour and Welfare, Tokyo, [in Japanese].
12. Japan Pediatric Society Nipon syonika gakai no yobousessyu no douji sessyu ni taisuru kangaekata 28 April 2011, [in Japanese]. http://www.jpeds.or.jp/pi-j.html.
13. Ministry of Health, Labour and Welfare Report on health center activities and health services for the aged 2008 2010, Health and Welfare Statistics Association, Tokyo, [in Japanese].
14. Iwashita Y., Takemura S. Factors associated with willingness to undergo vaccination against Haemophilus influenzae type B (Hib). Nippon Koshu Eisei Zasshi 2010, 57(5):381-389. [in Japanese].
15. Ministry of Internal Affairs and Communications Population estimates of Japan 2002, Statistics Bureau, Tokyo.
16. Iwata S., Ishiwada N., Sakata H., Sakano T., Sato Y., Nakano T., et al. Burden of illness of bacterial meningitis and bacteremia caused by Streptococcus pneumonia in children. Jpn J Pediatr 2008, 61:2206-2220. [in Japanese].
17. Ministry of Health Labour Welfare Syoniyo haien kyukin wakutin, bihu wakutin no anzensei no hyouka kekka ni tuite 2011, Press release, March 24, 2011 [in Japanese].
18. Black S., Shinefield H., Fireman B., Lewis E., Ray P., Hansen J.R., et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children, Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000, 19(3):187-195.
19. Kim N.H., Lee J., Lee S.J., Lee H., Kim K.H., Park S.E., et al. Immunogenicity and safety of pneumococcal 7-valent conjugate vaccine [diphtheria CRM(197) protein conjugate; Prevenar] in Korean infants: differences that are found in Asian children. Vaccine 2007, 5(45):7858-7865.
20. Sakata H., Shirai M., Kaijino M., Takase M., Okamoto T., Niura N., et al. Epidemiological study of bacterial meningitis in children in Kamikawa subprefecture in Hokkaido between 1988 and 2002. Acta Paediatr Jpn 2004, 108:401-405. [in Japanese].
21. Zhou F., Bisgard K.M., Yusuf H.R., Deuson R.R., Bath S.K., Murphy T.V. Impact of universal Haemophilus influenzae type b vaccination starting at 2 months of age in the United States: an economic analysis. Pediatrics 2002, 110(4):653-661.
22. Ministry of Health, Labour and Welfare The 20th life tables 2007, Health and Welfare Statistics Association, Tokyo, [in Japanese].
23. Rozenbaum M.H., Sanders E.A., van Hoek A.J., Jansen A.G., van der Ende A., van den Dobbelsteen G., et al. Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the seven valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. BMJ 2010, 340:c2509.
24. Rodenburg G.D., de Greeff S.C., Jansen A.G., de Melker H.E., Schouls L.M., Hak E., et al. Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis 2010, 16(5):816-823.
25. Lepoutre A., Varon E., Georges S., Gutmann L., Lévy-Bruhl D. Impact of infant pneumococcal vaccination on invasive pneumococcal diseases in France, 2001-2006. Euro Surveill 2008, 13(August (35)).
26. Munoz-Almagro C., Jordan I., Gene A., Latorre C., Garcia-Garcia J.J., Pallares R. Emergence of invasive pneumococcal disease caused bynonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin infect Dis 2008, 46:174-182.
27. Ray G.T., Pelton S.I., Klugman K.P., Strutton D.R., Moore M.R. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States. Vaccine 2009, 27(47):6483-6494.
28. Kamiya H., Iwata S., Ishiwada N., Yamanaka M., Sugita R. Economic analysis of pneumococcal conjugate vaccination in Japan. Japanese Journal of Pediatrics 2008, 61:2233-2241. [in Japanese].
29. Yamanaka N., Hotomi M., Sugita R. Cost-effectiveness of pneumococcal conjugate vaccine in Japan: Estimation on acute pneumococcal otitis media in children. Japanese Journal of Pediatrics 2008, 61:2221-2232. [in Japanese].
30. Suzuki K., Kurono Y., Kobayashi T., Nishimura T., Baba S., Harabuchi Y., et al. The fourth nationwide survey of clinical isolates from patients with otolaryngological field infections. J Jpn Soc Infect Dis Otolaryngol 2008, 26:15-26. [in Japanese].
31. Hotomi M., Billal D.S., Kamide Y., Kanesada K., Uno Y., Kudo F., et al. Serotype distribution and penicillin resistance of Streptococcus pneumoniae isolates from middle ear fluids of pediatric patients with acute otitis media in Japan. Clin. Microbiol. 2008, 46:3808-3810.
32. Social Statistics Division, Statistics and Information Department, Minister's Secretariat, Ministry of Health, Welfare and Labour Heisei 20 nen kanja chosa 2008, Ministry of Health, Welfare and Labour, Tokyo, [in Japanese].
33. Ministry of Health, Labour and Welfare Vital statistics of Japan 2006 2008, Health and Welfare Statistics Association, Tokyo, [in Japanese].
34. Lucero M.G., Dulalia V.E., Nillos L.T., Williams G., Parreño R.A.N., Nohynek H., et al. Pneumococcal conjugate vaccines for preventing vaccine-type invasive pneumococcal disease and X-ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev 2009, (4). Art. No.: CD004977. 10.1002/14651858.CD004977.pub2.
35. Chiba N., Morizumi M., Sunaoshi K., Takahashi S., Sunakawa K., Ubukata K., et al. Serotype and antibiotic resistance of isolates from patients with invasive pneumococcal disease in Japan. Epidemiol Infect 2010, 138:61-68.
36. Drummond M.F., Sculpher M.J., Torrance G.W., O'Brien B.J., Stoddart G.L. Methods for economic evaluation of health care programmes 2004, Oxford University Press, Oxford. 3rd ed.
37. Ishiwada N., Iwata S., Sakata H., Sakano T., Sato Y., Nakano T., et al. Burden of illness of pneumonia caused by Streptococcus pneumoniae in children. Japanese Journal of Pediatrics 2008, 61:2194-2204. [in Japanese].
38. Ministry of Health Labour Welfare Basic survey on wage structure 2009 2010, Health and Welfare Statistics Association, Tokyo, [in Japanese].
39. Leino T., Takala T., Auranen K., Mäkelä P.H., Takala A.K. Indirect protection obtained by Haemophilus influenza type b vaccination: analysis in a structured population model. Epidemiol Infect 2004, 132:959-966.
40. Ministry of Health, Labour and Welfare Comprehensive survey of living conditions of the people on health and welfare 2009 2010, Health and Welfare Statistics Association, Tokyo, [in Japanese].
41. Shiroiwa T., Sung Y.K., Fukuda T., Lang H.C., Bae S.C., Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?. Health Econ 2010, 19(4):422-437.
42. World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. WHO Document Production Services: Geneva, Switzerland; 2008.
43. Isaacman D.J., Strutton D.R., Kalpas E.A., Horowicz-Mehler N., Stern L.S., Casciano R., et al. The impact of indirect (herd) protection on the cost-effectiveness of pneumococcal conjugate vaccine. Clin Ther 2008, 30(2):341-357.